UK-based biopharmaceutical company Orchard Rx Ltd. announced that it aims to secure $200 million in an initial public offering (IPO).
The company intends to issue 13.3 million shares at a price of $14 to $16 per share.
Orchard has a market capitalization of $1.2 billion.
U.S.-based financial services companies J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.